linjc16/ctgov huggingface dataset:
Transcranial Direct Current Stimulation for Migraine Attack

Study Overview
=================
Brief Summary
-----------------
This study is conducted to investigate the therapeutic efficacy and safety of transcranial direct current stimulation (tDCS) over the primary motor cortex of patients with acute migraine attack.

Official Title
-----------------
Manho Kim, MD, PhD Professor, Neurology Seoul National University Hospital,

Conditions
-----------------
Acute Migraine

Intervention / Treatment
-----------------
* Procedure: transcranial direct current stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 17-70 years Migraine With or without aura The first attack of migraine was earlier than 50 years of age One to 8 moderate to severe migraine attacks per month in the 2 months preceding the screening Willing and able to give written informed consent Able to read, comprehend and complete the diary form Exclusion Criteria: Not able to distinguish between migraine and non-migraine headache Combined headache, including the tension type headache and medication overuse headache Pregnant, actively trying to become pregnant or breast-feeding women Uncontrolled and significant medical illness Vertebrobasilar or hemiplegic migraine according to the International Headache Society diagnostic criteria Having intracranial metal implants or a cardiac pacemaker A history of epilepsy or other organic brain disorders A history of psychological diseases Having changed medications for migraine within 1 month before giving us informed consent Drug abuser or alcoholics

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: migraine<br> | Procedure: transcranial direct current stimulation<br>* A constant current of 2 mA intensity applied for 20 min over C3 or C4<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants who experienced pain relief of one level or more |  | at 2h post-treatment |
Prospective Randomized On-X Versus SJM Evaluation Trial

Study Overview
=================
Brief Summary
-----------------
The study hypothesizes that rate of thromboembolic complications of the On-X prosthesis is reduced as compared to the SJM prosthesis.

Detailed Description
-----------------
The study is a multi-centre, randomized trial that will sequentially enroll up to 500 eligible patients in each group from up to 10 participating study centres internationally to test the hypothesis.

Official Title
-----------------
Thromboembolic Related Complications in a Randomized Trial of Previous and Current Generation Mechanical Valve Prostheses

Conditions
-----------------
Heart Valve Disease

Intervention / Treatment
-----------------
* Device: On-X Heart valve replacement
* Device: SJM Heart valve replacement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient requires an isolated mitral or isolated aortic valve replacement. (Patients undergoing coronary artery bypass and / or concomitant repair of mitral or tricuspid valves are eligible.) The patient is a candidate for receipt of a mechanical heart valve. The patient (or legal guardian) has signed a study-specific informed consent form agreeing to the randomization, data collection and follow-up requirements. The patient can be having a re-operative procedure, so long as the previous prosthetic valve is explanted and the patient does not become a double valve implantation patient. Exclusion Criteria: The patient is not a candidate to receive a mechanical heart valve. The patient already has a prosthetic valve other than the valve(s) being replaced at this time. The patient requires a tricuspid valve replacement. The patient is enrolled in another investigative study or trial.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ONX<br>On-X heart Valve Replacement | Device: On-X Heart valve replacement<br>* On-X Heart valve replacement<br>* Other names: On-X Prosthetic Heart Valve;|
| Active Comparator: SJM<br>SJM heart valve replacement | Device: SJM Heart valve replacement<br>* SJM Heart valve replacement<br>* Other names: St. Jude Medical Prosthetic Heart Valve;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thromboembolisms | Frequency of occurrence for thromboembolic events, either major or reversible, as a function of valve type. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thromboembolism, mechanical heart valves, randomized
The Effect of Different Focusing Methods on Muscle Activity

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the effects of different focusing methods on muscular activity

Detailed Description
-----------------
After the first data collecting ( Demographic data, Inclusion criteria) surface electromyography EMG evaluations will be taken from 6 muscles( Vastus Medialis, Rectus Femoris, Vastus Lateralis, Biceps Femoris, Semitendinosus, Gluteus Medius). These recordings will be taken in 3 different circumstances: 1- Without a focusing method 2- With an external focus and 3- With an internal focus

Official Title
-----------------
The Effect of Different Focusing Methods on Muscle Activity During The Single Leg Squat Movement

Conditions
-----------------
Knee Injuries and Disorders

Intervention / Treatment
-----------------
* Other: Single leg squat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Being between the ages of 18-25 Having a Body Mass Index between 18.5-24.9 Exclusion Criteria: Having trauma/surgery involving the lower extremity in the last 6 months or having any disorder affecting hip and knee muscle function Foot Posture Index score not being between 0 and +5 Hamstring Flexibility- Sit and Reach Test score greater than +5 cm Restricted ankle dorsiflexion angle (It will be expected to be at least 5 degrees more than neutral)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Single leg squat without a clue or focusing method Single leg squat with an external focus Sinlge leg squat with an internal focus | Other: Single leg squat<br>* Single leg squat exercise in different circumstances<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surface Electromyography | Surface EMG evaluations of Vastus Medialis, Vastus Lateralis, Rectus Femoris, Biceps Femoris, Semitendinosus and Gluteus Medius Muscles in 3 conditions in a row(Without a focusing method, With an internal focus, With an external focus | Procedure (During the intervention) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Foot Posture Index | Evaluations of Foot by inspection | Baseline, for inclusion criteria | 
| Sit and Reach Test | Assessment of hamstring flexibility | Baseline, for inclusion criteria | 
| Gluteus Medius Muscle Dynamometer Assessment | Assessment of Gluteus Medius Strength | Baseline, for inclusion criteria | 
| Ankle Dorsi Flexion Goniometer Assessment | Assessment of Dorsiflexion | Baseline, for inclusion criteria | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
single leg squat, muscular activity, knee alignment
Pulmonary Embolism and COVID-19

Study Overview
=================
Brief Summary
-----------------
The charts of patients who developed pulmonary embolism in the course of COVID-19 will be evaluated, retrospectively. Clinical features and laboratory data will be analyzed.

Detailed Description
-----------------
Patients with COVID-19 infection will be evaluated retrospectively. Demographic data, clinical and laboratory findings will be recorded. Findings of patients with pulmonary embolism and withour pulmonary embolism will be compared.

Official Title
-----------------
Evaluation of the Patients With COVID-19 in Terms of Pulmonary Embolism

Conditions
-----------------
Pulmonary Embolism, Covid-19

Intervention / Treatment
-----------------
* Other: intensive care unit admission ratio


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - All patients with positive RT-PCR for COVID-19 Exclusion Criteria: - All patients with negative RT-PCR for COVID-19

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Covid-19 Patients with Pulmonary embolism<br>Clinically demonstared cases infected with COVID-19 who developed pulmonary embolism. | Other: intensive care unit admission ratio<br>* intensive care unit admission ratio<br>|
| Covid-19 Patients without Pulmonary embolism<br>Clinically demonstared cases infected with COVID-19 who did not develop pulmonary embolism. | Other: intensive care unit admission ratio<br>* intensive care unit admission ratio<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pulmonary embolism | development of pulmonary embolism | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intensive care unit | need for admission to intensive care unit | 1 year | 
| mortality | mortality rate due to pulmonary embolism | 1 year |
Is High Sensibility Troponins a Dialysable Marker in Hemodialysis Patients and Does it Have Prognostic Value?

Study Overview
=================
Brief Summary
-----------------
Evaluation of High sensibility troponin levels modification by hemodialysis in terminal renal failure patient at Sherbrooke University Hospital Center as determined by serial measurements. Verification of potential effects of these levels and their variation as predictors of cardiovascular outcomes and events at 6 and 12 months.

Detailed Description
-----------------
Recruiting of hemodialysis patients of the nephrology renal supplementation clinics at Sherbrooke University Hospital Center to measure three blood level of high-sensibility troponins before and after standard dialysis. Verification on the variation of these levels after dialysis. Follow-up at 6 and 12 months of the patient for Cardiovascular events and death and verification of a possible predictive value of troponin blood levels for these events.

Official Title
-----------------
Is High Sensibility Troponins a Dialysable Marker in Hemodialysis Patients and Does it Have Prognostic Value?

Conditions
-----------------
Renal Failure

Intervention / Treatment
-----------------
* Other: Hs-TNT dosage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: over 50 years, no symptoms, over 1 months of hemodialysis Exclusion Criteria: 1 or more in the last month; Acute coronary syndrome, Heart failure decompensated, Myo or Pericarditis, Pulmonary embolism, Sepsis/shock, Stroke or transient ischemic attack, Malignant high blood pressure, Arrythmia, electrical cardio-version, major trauma, significant burnings (>25%), Chemotherapy, Cardiovascular surgery, percutaneous angio-intervention, Chronic systemic disease (sarcoidosis, amyloidosis, LED, Etc.)

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Hs-TnT<br>Hs-TNT dosage | Other: Hs-TNT dosage<br>* Bloodwork before and after hemodialysis for high sensibility troponins T blood level<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| High sensibility troponins T blood level variation | Verification of high sensibility troponins T blood after classical hemodialysis compared to pre-treatment levels. | 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prognostic value of high sensibility troponins T blood level variation | Evaluation of a potential prognosis value of high sensibility troponins T blood levels and its variation after hemodialysis. | at 6 and 12 months |
Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia

Study Overview
=================
Brief Summary
-----------------
Pseudomonas aeruginosa is one of the major causative microorganisms of ventilator-associated pneumonia often resistant to antibiotics. In experimental models, nebulization of antibiotics delivers high lung tissue concentrations of antibiotics in infected lungs and increases lung bacterial killing. The aim of the study is to assess the efficiency of nebulized ceftazidime and amikacin in the treatment of pneumonia caused by Pseudomonas aeruginosa in ventilated patients.

Official Title
-----------------
Assessment of Efficiency of Nebulized Ceftazidime and Amikacin in Treatment of Ventilator Associated Pneumonia Caused by Pseudomonas Aeruginosa

Conditions
-----------------
Pneumonia

Intervention / Treatment
-----------------
* Drug: ceftazidime and amikacin
* Drug: ceftazidime and amikacin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female >18 years old, ventilator associated pneumonia caused by pseudomonas aeruginosa Written informed consent provided by the relatives Exclusion Criteria: Pseudomonas aeruginosa resistant to ceftazidime and amikacin Pseudomonas aeruginosa pneumonia associated with other infections requiring intravenous treatment Severe septic shock and severe hypoxemia Allergy to ceftazidime or amikacin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1: nebulized ceftazidime and amikacin<br> | Drug: ceftazidime and amikacin<br>* Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days<br>* Other names: fortum and amiklin;|
| Active Comparator: 2: intravenous ceftazidime and amikacin<br> | Drug: ceftazidime and amikacin<br>* Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days<br>* Other names: fortum and amiklin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bacterial killing |  | 14 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes of lung aeration |  | 8 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nebulization, ceftazidime, amikacin, pneumonia, Pseudomonas aeruginosa, mechanical ventilation, Ventilator-associated pneumonia, treatment
Analysis of the Results From Influenza Rapid Test A Positive and H1N1 Real Time RT-PCR

Study Overview
=================
Brief Summary
-----------------
The first outbreak of a new H1N1 influenza pandemic originated in the North America in April 2009. As of July 1, 2009, a total of 77,201 cases were accumulated in 103 countries around the world and the mortality rate of was about 0.43%. Alignment and analysis on gene sequences of the new H1N1 influenza virus found that it contains extremely homologous gene composition with that of the swine influenza viruses (swine flu) identified in Europe and North America in last century. Thus the virus strain was later renamed as a novel influenza H1N1. In general, the symptoms caused by the new influenza H1N1 infection was very similar to those resulted from seasonal influenza viral infection. Thus, it is difficult to distinguish the various influenza strains responsible for the infections only by clinical appearance. To compare the accuracy, specificity and sensitivity and speed in identifying the new influenza H1N1 in suspected cases, the investigators extracted RNA from influenza A-positive reactive specimens identified by a Influenza Rapid Test, for a Real-time PCR method to further detect the presence of swine H1 gene. In addition, the titer of H1N1 virus, the color development on the test stripe and clinical symptoms in patients were significantly associated. Finally, Real-time PCR products were subjected to sequence determination to explore potential new influenza pathogenicity, transmissibility and drug usage.

Official Title
-----------------
Analysis of the Results From Influenza Rapid Test A Positive and H1N1 Real Time RT-PCR

Conditions
-----------------
H1N1 Influenza Virus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Influenza Rapid Test Influenza A(+) B(-) Influenza Rapid Test Influenza A(+) B(+) Influenza Rapid Test Influenza A(-) B(-) was negative control Exclusion Criteria: Influenza Rapid Test Influenza A(-) B(+)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental Group<br> | |
| Control Group<br> | |
| Negative control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
H1N1 Influenza virus, swine flu, Real Time RT-PCR
Validity of a Supersimplified Device for Diagnosis of Patients With Suspected Obstructive Sleep Apnoea-hypopnoea (OSAH)

Study Overview
=================
Brief Summary
-----------------
The diagnosis of OSASH requires expensive sleep tests that generate long waiting lists, so we need simplified and rapid diagnostic tools. The ApneaLinkTM, is a device that allows the assessment of respiratory events by measuring the flow ventilation with a nasal cannula connected to a pressure transducer.

Official Title
-----------------
Validity of a Supersimplified Device for Diagnosis of Patients With Suspected Obstructive Sleep Apnoea-hypopnoea (OSAH).

Conditions
-----------------
Obstructive Sleep Apnea

Intervention / Treatment
-----------------
* Procedure: PSG
* Procedure: MicroMESAM system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients 18 to 75 years of both sexes. clinical suspicion of OSAH defined as subjects with breathing pauses during sleep and / or asphyxiated sounds, with or without excessive daytime sleepiness as measured by the Epworth scale and who have asked for a sleep test to rule out OSAH. Informed consent signed by the patient. Exclusion Criteria: Place of residence more than 100 km from the hospital. inability to perform psychophysical study at home. cardio-vascular disease, cerebro-vascular or respiratory or acute severe unstable as to preclude the proper conduct of studies at home and / or PSG in the laboratory. Patients with chronic insomnia or recognize sleep less than six hours. Patients with depression (both point 4 and 5 are the potential causes of false negatives in a PR for lack of sufficient sleep time). nasal obstruction complete or nearly complete, which prevents obtaining a quality signal with MicroMESAM

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MicroMESAM<br>Sleep study made by MicroMESAM system | Procedure: MicroMESAM system<br>* Sleep study made by MicroMESAM system<br>|
| Active Comparator: PSG<br>Sleep study made by PSG (polysomnography) | Procedure: PSG<br>* Sleep study made by PSG (polysomnography)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients correctly diagnosed by MicroMESAM (APNEA-LINK) |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sleep apnoea, Diagnosis, Blood pressure, Body mass index, Breath analysis